-DOCSTART- -X- O
Dengue -X- _ B-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
DENV -X- _ I-Patient
) -X- _ I-Patient
is -X- _ O
the -X- _ O
causative -X- _ O
agent -X- _ O
of -X- _ O
dengue -X- _ O
fever -X- _ O
and -X- _ O
dengue -X- _ O
hemorrhagic -X- _ O
fever. -X- _ O
The -X- _ O
virus -X- _ O
is -X- _ O
endemic -X- _ O
in -X- _ O
over -X- _ O
120 -X- _ O
countries -X- _ O
, -X- _ O
causing -X- _ O
over -X- _ O
350 -X- _ O
million -X- _ O
infections -X- _ O
per -X- _ O
year. -X- _ O
Dengue -X- _ O
vaccine -X- _ O
development -X- _ O
is -X- _ O
challenging -X- _ O
because -X- _ O
of -X- _ O
the -X- _ O
need -X- _ O
to -X- _ O
induce -X- _ O
simultaneous -X- _ O
protection -X- _ O
against -X- _ O
four -X- _ O
antigenically -X- _ O
distinct -X- _ O
DENV -X- _ O
serotypes -X- _ O
and -X- _ O
evidence -X- _ O
that -X- _ O
, -X- _ O
under -X- _ O
some -X- _ O
conditions -X- _ O
, -X- _ O
vaccination -X- _ O
can -X- _ O
enhance -X- _ O
disease -X- _ O
due -X- _ O
to -X- _ O
specific -X- _ O
immunity -X- _ O
to -X- _ O
the -X- _ O
virus. -X- _ O
While -X- _ O
several -X- _ O
live-attenuated -X- _ O
tetravalent -X- _ O
dengue -X- _ O
virus -X- _ O
vaccines -X- _ O
display -X- _ O
partial -X- _ O
efficacy -X- _ O
, -X- _ O
it -X- _ O
has -X- _ O
been -X- _ O
challenging -X- _ O
to -X- _ O
induce -X- _ O
balanced -X- _ O
protective -X- _ O
immunity -X- _ O
to -X- _ O
all -X- _ O
4 -X- _ O
serotypes. -X- _ O
Instead -X- _ O
of -X- _ O
using -X- _ O
whole-virus -X- _ O
formulations -X- _ O
, -X- _ O
we -X- _ O
are -X- _ O
exploring -X- _ O
the -X- _ O
potentials -X- _ O
for -X- _ O
a -X- _ O
particulate -X- _ O
subunit -X- _ O
vaccine -X- _ O
, -X- _ O
based -X- _ O
on -X- _ O
DENV -X- _ O
E-protein -X- _ O
displayed -X- _ O
on -X- _ O
nanoparticles -X- _ O
that -X- _ O
have -X- _ O
been -X- _ O
precisely -X- _ O
molded -X- _ O
using -X- _ O
Particle -X- _ O
Replication -X- _ O
in -X- _ O
Non-wetting -X- _ O
Template -X- _ O
( -X- _ O
PRINT -X- _ O
) -X- _ O
technology. -X- _ O
Here -X- _ O
we -X- _ O
describe -X- _ O
immunization -X- _ O
studies -X- _ O
with -X- _ O
a -X- _ O
DENV2-nanoparticle -X- _ B-Intervention
vaccine -X- _ I-Intervention
candidate. -X- _ I-Intervention
The -X- _ O
ectodomain -X- _ O
of -X- _ O
DENV2-E -X- _ O
protein -X- _ O
was -X- _ O
expressed -X- _ O
as -X- _ O
a -X- _ O
secreted -X- _ O
recombinant -X- _ O
protein -X- _ O
( -X- _ O
sRecE -X- _ O
) -X- _ O
, -X- _ O
purified -X- _ O
and -X- _ O
adsorbed -X- _ O
to -X- _ O
poly -X- _ O
( -X- _ O
lactic-co-glycolic -X- _ O
acid -X- _ O
) -X- _ O
( -X- _ O
PLGA -X- _ O
) -X- _ O
nanoparticles -X- _ O
of -X- _ O
different -X- _ O
sizes -X- _ O
and -X- _ O
shape. -X- _ O
We -X- _ O
show -X- _ O
that -X- _ O
PRINT -X- _ O
nanoparticle -X- _ O
adsorbed -X- _ O
sRecE -X- _ O
without -X- _ O
any -X- _ O
adjuvant -X- _ O
induces -X- _ O
higher -X- _ B-Intervention
IgG -X- _ I-Intervention
titers -X- _ I-Intervention
and -X- _ I-Intervention
a -X- _ I-Intervention
more -X- _ I-Intervention
potent -X- _ I-Intervention
DENV2-specific -X- _ I-Intervention
neutralizing -X- _ I-Intervention
antibody -X- _ I-Intervention
response -X- _ I-Intervention
compared -X- _ O
to -X- _ O
the -X- _ O
soluble -X- _ O
sRecE -X- _ O
protein -X- _ O
alone. -X- _ O
Antigen -X- _ B-Outcome
trafficking -X- _ I-Outcome
indicate -X- _ I-Outcome
that -X- _ I-Outcome
PRINT -X- _ I-Outcome
nanoparticle -X- _ I-Outcome
display -X- _ I-Outcome
of -X- _ I-Outcome
sRecE -X- _ I-Outcome
prolongs -X- _ I-Outcome
the -X- _ I-Outcome
bio-availability -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
antigen -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
draining -X- _ I-Outcome
lymph -X- _ I-Outcome
nodes -X- _ I-Outcome
by -X- _ I-Outcome
creating -X- _ I-Outcome
an -X- _ I-Outcome
antigen -X- _ I-Outcome
depot. -X- _ I-Outcome
Our -X- _ O
results -X- _ O
demonstrate -X- _ O
that -X- _ O
PRINT -X- _ B-Outcome
nanoparticles -X- _ I-Outcome
are -X- _ I-Outcome
a -X- _ I-Outcome
promising -X- _ I-Outcome
platform -X- _ I-Outcome
for -X- _ I-Outcome
delivering -X- _ I-Outcome
subunit -X- _ I-Outcome
vaccines -X- _ I-Outcome
against -X- _ I-Outcome
flaviviruses -X- _ I-Outcome
such -X- _ I-Outcome
as -X- _ I-Outcome
dengue -X- _ I-Outcome
and -X- _ I-Outcome
Zika -X- _ I-Outcome
. -X- _ O

